ten23 health’s Post

✨ Looking forward to the collaboration with Ypsomed AG, and Reto Jost and team to advance the commercialization of the #YpsoDose wearable injector for the subcutaneous self-injection of large-volume doses.   Read more about this in today's press release: https://ow.ly/Z8HQ50Rg1Fn   https://lnkd.in/e5csnd5J   Providing integrated, #patientcentric drug/device solutions is key for ten23 health´s mission. The #YpsoDose will provide wonderful, additional opportunities (for patients and Pharma companies alike) - on top of autoinjectors and other parenteral delivery devices available in the market already (and also offered by ten23 with other partnerships) 🧑🏽⚕️   #ten23health #press #injectables #parenterals #cdmo #subcutaneous #SCdelivery #pharmaceuticalmanufacturing #pharmaceuticalpackaging #drugsafety #patientsafety #aseptic #Patients

An important step for YpsoDose and a good illustration of Ypsomed's networking approach!

Gain insights into drug delivery via an on-body patch infusor developed by Gerresheimer from Sabine Websky, Head of Medical Affairs & Applied Technologies! The subcutaneous route of drug administration is increasingly popular, particularly self-administration, due to the high costs associated with intravenous administration and the patient advantages of therapy in a home-care setting. This presentation looks at the advantages of subcutaneous delivery compared to intravenous administration. It further discusses the effectiveness of subcutaneous delivery of small molecule drugs via an on-body infusor. Evidence will be presented from clinical studies of a novel furosemide formulation delivered subcutaneously via an on-body patch infusor developed by Gerresheimer. Gerresheimer is a Silver Sponsor at Combination Products Summit! Be sure to stop by their booth and say hello 👋 ! Register for this conference or learn more on our website: https://lnkd.in/eY8w4jNc #combinationproducts #clinicalstudy #infusor #drugadministration #medicaldevices #biotechnology #drugdelivery #pharmaevent

𝐌𝐞𝐝𝐭𝐫𝐨𝐧𝐢𝐜 𝐝𝐨𝐮𝐛𝐥𝐞𝐬 𝐝𝐨𝐰𝐧 𝐢𝐭𝐬 𝐞𝐧𝐝𝐨𝐬𝐜𝐨𝐩𝐲 𝐀𝐈 𝐢𝐧 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐰𝐢𝐭𝐡 𝐂𝐨𝐬𝐦𝐨🩺 𝗜𝗻 𝗗𝗲𝗰𝗲𝗺𝗯𝗲𝗿 𝟮𝟬𝟮𝟯, Medtronic is doubling down its AI (#artificialintelligence) in partnership with Cosmo Pharmaceuticals💊, a developer of plug-in software for spotting #healthissues automatically during #endoscopicexams. Cosmo has received FDA (Food and Drug Administration) clearance for its GI Genius system💡 that highlights polyps and #cancerlesions in real time during colonoscopy including human eye 👁️might miss. The medtech giant has planned to expand its collaboration with aim of building a #portfolio which is capable of hosting multiple AI-powered diagnostics gathered from third-party developers🏥. ➤ 𝑶𝒕𝒉𝒆𝒓 𝒓𝒆𝒍𝒂𝒕𝒆𝒅 𝒓𝒆𝒑𝒐𝒓𝒕:https://bit.ly/3TlD40t #MedicalImaging #medicaldevices #health #prophecy #marketresearch #prophecymarketinsights

Did you know that Congruence Medical Solutions aims to enhance drug delivery for injectable medications with complex needs?    Introducing Congruence Medical Solutions, a business featured in our CPHI Disruptor Watchlist. Congruence uses its robust technology IP to create high-value drug delivery devices catering to various therapeutic areas. As pioneers in ophthalmic drug delivery, they have developed the award-winning Microliter Dosing Syringe.    The company's technology platforms not only facilitate the commercialization of the next generation of injectable drugs but also extend the commercial viability of existing drugs by offering differentiation.    Gautam Shetty, the Founder and CEO, sheds light on Congruence’s impact on drug commercialization: “Congruence’s technology platforms enable the commercialization of the next generation of injectable drugs and help extend the commercial runway for drugs through differentiation.” #Congruence #ChemicalIndustry #MedicalSolutions

Thoughts on this? >> Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #productmarketing #pharma #pharmaceutical

Thoughts on this? >> Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharma #productmarketing #pharmaceutical

Solving the problems surrounding critical drug delivery for the best possible patient experience is a global issue.    That’s why Windgap Medical, Inc. is thrilled to participate in the 2023 PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Gothenburg, Sweden.    This conference provides a unique opportunity for leaders in the industry from all over the world to learn, share, debate, and collaborate on our common challenges, all while driving innovation in injectable drug delivery.     We invite you to meet us at Booth G33 to discuss how our technologies will help shape the future of drug delivery. Kevin Deane, Business Development Advisor at Windgap Medical, will also share recent developments in a Tech Talk on October 18 at 3:25 p.m.    2023 PDA Universe of Pre-Filled Syringes and Injection Devices Conference  Oct 17 - Oct 18, 2023   Gothenburg, Sweden PDA - Parenteral Drug Association #DrugDelivery

Global PharmaPartners, Inc (GPP) has for licensing many ANDA & 505(b)(2) COMPLEX INJECTABLES. Complex injectables are designed to infuse drugs through a hollow needle and a syringe, which is penetrated through the skin into the body with a bulk drug over time (days, weeks, months). The Complex injectable market is gaining traction in injectable therapies/infusion treatment owing to increased use in life-threatening and chronic disease treatments. These GPP products are simplifying the current use of auto-injectors, dual chamber auto-injectors, and metered dose inhalers; other products where complexity or uncertainty concerning the approval pathway or possible alternative approaches would benefit from GPP's development partners' early scientific engagement and technology resulting in faster approval ahead of all generics and highly profitable investment opportunities. Please follow up with Rob Camerer regarding these excellent opportunities. Rob Camerer - robcamerer@globalpharmapartners.com cel: +1(417)7704600 (WhatsApp the same)

How can we use behavioural science models to tackle injection errors and improve patient outcomes? Don't miss the joint presentation with Dr. Sabine A. Krawietz of Novartis and Team Consulting's Benjamin Cox at PDA Digitalization in Pharma & Medical Devices Conference. We look forward to seeing you there! Date: Tuesday 4th June 2024 Time: 5:00pm - 5:20pm CEST Session 3: Behaviour Science - Designing for Engagement PDA - Parenteral Drug Association #digitalhealth #behaviouralscience